Interferon beta drug is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug does not completely cure the condition, but slows down progression of some of the disabling effects and decreases the number of relapses of the disease. Interferons are natural substances produced in the human body to help fight infections. Interferon beta drugs are categorized in Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A.
Market Dynamics
Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, in 2017, this autoimmune condition affects 2.5 million people with an annual global incidence of around 7 cases per 100,000 people. The study also states that prevalence rates vary between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000. Moreover, according to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Thus, increasing prevalence of multiple sclerosis is a major factor driving the growth of global interferon beta drugs market.
Key features of the study:
- This report provides in-depth analysis of the global interferon beta drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global interferon beta drugs market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Biogen Idec., Merck KGaA, Novartis Pharmaceuticals Corporation, and Bayer
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global interferon beta drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interferon beta drugs market.
Detailed Segmentation:
- Global Interferon Beta Drugs Market, By Product Type:
- Interferon Beta-1A
- Interferon Beta-1B
- Peginterferon Beta-1A
- Global Interferon Beta Drugs Market, By Route of Administration:
- Intramuscular
- Subcutaneous
- Intravenous
- Global Interferon Beta Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Interferon Beta Drugs Market, By Region:
- North America
- By Product Type:
- Interferon Beta-1A
- Interferon Beta-1B
- Peginterferon Beta-1A
- By Route of Administration:
- Intramuscular
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Product Type:
- Interferon Beta-1A
- Interferon Beta-1B
- Peginterferon Beta-1A
- By Route of Administration:
- Intramuscular
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type:
- Interferon Beta-1A
- Interferon Beta-1B
- Peginterferon Beta-1A
- By Route of Administration:
- Intramuscular
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- Interferon Beta-1A
- Interferon Beta-1B
- Peginterferon Beta-1A
- By Route of Administration:
- Intramuscular
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type:
- Interferon Beta-1A
- Interferon Beta-1B
- Peginterferon Beta-1A
- By Route of Administration:
- Intramuscular
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- Interferon Beta-1A
- Interferon Beta-1B
- Peginterferon Beta-1A
- By Route of Administration:
- Intramuscular
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles:
- Biogen Idec
- Merck KGaA
- Novartis Pharmaceuticals Corporation
- Bayer
“*” marked represents similar segmentation in other categories in the respective section.
